

Anti-IL17A/IL-17F Antibody (Bimekizumab)

Introduction

Bimekizumab is a monoclonal antibody that targets interleukin (IL)-17A and IL-17F, cytokines involved in the inflammatory process. It was developed by UCB, a global biopharmaceutical company. Bimekizumab consists of a humanized IgG1 monoclonal antibody. Its mechanism of action involves dual inhibition of IL-17A and IL-17F, which helps reduce inflammation and modulate the immune response. It is primarily used to treat moderate to severe plaque psoriasis and is being studied for other inflammatory diseases such as psoriatic arthritis and ankylosing spondylitis.

Product parameters

Alternative Names	UCB4940, BIMZELX
Target Accession	-
Target	IL17A/IL-17F
CAS number	1418205-77-2
Molecular Weight	-
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years

Note

1. This product is for scientific research use only.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

